Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASi-HF Preserved
NCT06424288Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2024
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 30
01
Overview
A Phase 3 trial of vicadrostat in heart failure (HF), sponsored by Boehringer Ingelheim. Started Jun 2024; status: recruiting.
02
Drugs
vicadrostat
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06424288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424288.